Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.
Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.